0000000000437160

AUTHOR

Stefano Carugo

0000-0002-5166-0899

showing 7 related works from this author

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

2020

Several factors have been proposed to explain the high death rate of the coronavirus disease 2019 (COVID-19) outbreak, including hypertension and hypertension-related treatment with Renin Angiotensin System inhibitors. Also, age and multimorbidity might be confounders. No sufficient data are available to demonstrate their independent role. We designed a cross-sectional, observational, multicenter, nationwide survey in Italy to verify whether renin-angiotensin system inhibitors are related to COVID-19 severe outcomes. We analyzed information from Italian patients diagnosed with COVID-19, admitted in 26 hospitals. One thousand five hundred ninety-one charts (male, 64.1%; 66±0.4 years) were r…

MaleCross-sectional studyAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyRenin-Angiotensin System0302 clinical medicine80 and overMedicineodds ratioodds ratio.030212 general & internal medicineViralYoung adultSocieties MedicalAged 80 and overCOVID-19; hypertension; Italy; multimorbidity; odds ratio; Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Coronavirus Infections; Cross-Sectional Studies; Female; Humans; Hypertension; Italy; Male; Middle Aged; Multimorbidity; Pandemics; Pneumonia Viral; Prognosis; Renin-Angiotensin System; Survival Rate; Young Adult; Betacoronavirus; Societies MedicalMortality rateAge FactorsMiddle AgedPrognosisSurvival RateItalyCOVID-19; hypertension; Italy; multimorbidity; odds ratioFemaleCoronavirus InfectionsAdultmedicine.medical_specialtyhypertensionAdolescentmultimorbidityPneumonia ViralCOVID-19; Italy; hypertension; multimorbidity; odds ratio03 medical and health sciencesAngiotensin Receptor AntagonistsYoung AdultBetacoronavirusAge DistributionInternal medicineDiabetes mellitusMedicalInternal MedicineHumansSurvival ratePandemicsAgedbusiness.industrySARS-CoV-2COVID-19Odds ratioPneumoniamedicine.diseaseCross-Sectional StudiesHeart failureCOVID-19; Hypertension; Italy; Multimorbidity; Odds ratio; Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; COVID-19; Coronavirus Infections; Cross-Sectional Studies; Female; Humans; Hypertension; Italy; Male; Middle Aged; Multimorbidity; Pandemics; Pneumonia Viral; Prognosis; Renin-Angiotensin System; SARS-CoV-2; Survival Rate; Young Adult; Betacoronavirus; Societies MedicalbusinessSocietiesKidney disease
researchProduct

World Hypertension Day 2021 in Italy: Results of a Nationwide Survey

2022

Introduction: Hypertension is the biggest contributor to the global burden of cardiovascular diseases and related death, but the rates of hypertension awareness, treatment, and control remain largely perfectible. Methods: During the XVII World Hypertension Day (May 17th, 2021), a nationwide cross-sectional opportunistic study endorsed by the Italian Society of Hypertension was conducted on volunteer adults ≥ 18 years to raise awareness of high blood pressure (BP). A questionnaire on major demographic/clinical features (sex, age, employment, education, BP status awareness, hypertension family/personal history, antihypertensive medications use) and BP measurement habits (≥1 BP measurement in …

AdultMaleSettore MED/14 - Nefrologiaawareness; blood pressure; hypertension; surveySettore MED/09 - Medicina InternaSARS-CoV-2AwareneCOVID-19Middle AgedAwarenessCross-Sectional StudiesRisk FactorsSurveys and QuestionnairesAwareness Blood pressure Hypertension SurveyHypertensionInternal MedicineBlood pressureHumansFemaleAwareness; Blood pressure; Hypertension; Survey; Adult; Aged; Antihypertensive Agents; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Risk Factors; SARS-CoV-2; Surveys and Questionnaires; COVID-19; HypertensionCardiology and Cardiovascular MedicineSurveyAntihypertensive AgentsAged
researchProduct

Vorapaxar in the secondary prevention of atherothrombotic events

2012

BACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients …

MalePyridines[SDV]Life Sciences [q-bio]Myocardial InfarctionMedizinKaplan-Meier Estimate030204 cardiovascular system & hematologyBrain IschemiaLactones0302 clinical medicineMESH: Peripheral Arterial DiseaseSecondary PreventionMESH: Double-Blind Method030212 general & internal medicineMyocardial infarctionStrokeVorapaxarMESH: AgedAspirinMESH: Middle AgedMESH: RiskCardiovascular diseases [NCEBP 14]MESH: Secondary PreventionHazard ratioMESH: Brain IschemiaGeneral MedicineMiddle AgedClopidogrel3. Good healthStrokeMESH: Receptor PAR-1MESH: Myocardial Infarctionvorapaxar secondary prevention atherothrombotic eventsCardiovascular DiseasesMESH: Platelet Aggregation InhibitorsAnesthesiaRetreatmentPlatelet aggregation inhibitorFemaleIntracranial HemorrhagesMESH: HemorrhageMESH: Intracranial HemorrhagesMESH: Lactonescirculatory and respiratory physiologymedicine.drugRiskISQUEMIA CEREBRALHemorrhagePlaceboMESH: StrokePeripheral Arterial Disease03 medical and health sciencesDouble-Blind Method[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansReceptor PAR-1MESH: RetreatmentMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryMESH: PyridinesMESH: Cardiovascular Diseasesmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMESH: MalebusinessMESH: FemalePlatelet Aggregation Inhibitors
researchProduct

Lipoprotein(a) and aortic valve stenosis: A casual or causal association?

2022

Abstract Aims This review aims to provide an update of available methods for imaging calcification activity and potential therapeutic options. Data Synthesis: Aortic valve calcification represents the most common heart valve condition requiring treatment among adults in Western societies. No medical therapies are proven to be effective in treating symptoms or reducing disease progression. Therefore, surgical or transcatheter aortic valve replacement remains the only available treatment option. Elevated circulating concentrations of lipoprotein(a) is strongly associated with degenerative aortic stenosis. This relationship was first observed in prospective observational studies, and the causa…

Adultmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMedicine (miscellaneous)Settore MED/11 - Malattie dell'Apparato CardiovascolareAortic valve stenosisAortic valve calcification; Aortic valve stenosis; Drug therapy; Lipoprotein (a)Valve replacementLipoprotein (a)Internal medicinemedicineHumansProspective StudiesHeart valveNutrition and Dieteticsbiologybusiness.industryCalcinosisLipoprotein(a)medicine.diseaseObservational Studies as TopicStenosismedicine.anatomical_structureAortic ValveAortic valve stenosisAortic valve calcificationbiology.proteinCardiologyObservational studyDrug therapyAortic valve calcificationCardiology and Cardiovascular MedicinebusinessLipoprotein(a)CalcificationNutrition, Metabolism and Cardiovascular Diseases
researchProduct

May Measurement Month 2018: an analysis of blood pressure screening results from Italy

2020

Abstract Cardiovascular (CV) diseases are burdened by high mortality and morbidity, being responsible for half of the deaths in Europe. Although hypertension is recognized as the most important CV risk factor, hypertension awareness and blood pressure (BP) control are still unsatisfactory. In 2017, 30.6% of a >10 000 individual sample who took part in the May Measurement Month (MMM) campaign in Italy was found to have high BP. To raise awareness on the hypertension issue and to report BP data on a nation-wide scale in Italy. In the frame of the MMM campaign, an opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in May 2018. Blood pressure measurement, the def…

Mean arterial pressure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineDiabetes mellitusHealth careControlmedicineAcademicSubjects/MED00200030212 general & internal medicineRisk factor1102 Cardiorespiratory Medicine and HaematologyNational healthbusiness.industryHigh mortalityBlood pressure Control Hypertension Screening TreatmentArticlesmedicine.diseasehypertension; blood pressure; screening; treatment; controlTreatmentBlood pressureCardiovascular System & HematologyHypertensionBlood pressureScreeningCardiology and Cardiovascular MedicinebusinessBody mass indexBlood pressure; Control; Hypertension; Screening; TreatmentDemography
researchProduct

May Measurement Month 2019: an analysis of blood pressure screening results from Italy.

2021

Abstract Cardiovascular (CV) diseases are burdened by high mortality and morbidity, being responsible for half of the deaths in Europe. Although hypertension is recognized as the most important CV risk factor, hypertension awareness, and blood pressure (BP) control are still unsatisfactory. In 2017 and 2018, respectively >10 000 and >5000 individuals took part in the May Measurement Month (MMM) campaign in Italy, of whom 30.6% and 26.3% were found to have high BP, respectively. To raise public awareness on the importance of hypertension and to collect BP data on a nation-wide scale in Italy. In the frame of the MMM campaign, an opportunistic cross-sectional survey of volunteer…

Mean arterial pressure030204 cardiovascular system & hematology03 medical and health sciencesHealth personnel0302 clinical medicineHealth campaignDiabetes mellitusControlMedicineBlood pressure Control Screening TreatmentAcademicSubjects/MED00200030212 general & internal medicineMyocardial infarctionRisk factorTreatment.1102 Cardiorespiratory Medicine and HaematologySettore MED/14 - Nefrologiabusiness.industryArticlesmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareTreatmentBlood pressureCardiovascular System & HematologyHypertensionBlood pressureScreeningCardiology and Cardiovascular MedicinebusinessBody mass indexBlood pressure; Control; Hypertension; Screening; TreatmentDemographyEuropean heart journal supplements : journal of the European Society of Cardiology
researchProduct

Use of high flow nasal cannula in patients with acute respiratory failure in general wards under intensivists supervision: a single center observatio…

2022

Abstract Background Few data exist on high flow nasal cannula (HFNC) use in patients with acute respiratory failure (ARF) admitted to general wards. Rationale and objectives To retrospectively evaluate feasibility and safety of HFNC in general wards under the intensivist-supervision and after specific training. Methods Patients with ARF (dyspnea, respiratory rate-RR > 25/min, 150 < PaO2/FiO2 < 300 mmHg during oxygen therapy) admitted to nine wards of an academic hospital were included. Gas-exchange, RR, and comfort were assessed before HFNC and after 2 and 24 h of application. Results 150 patients (81 male, age 74 [60–80] years, SOFA 4 [2–4]), 123 with de-novo ARF underwent HFNC wi…

MaleRespiratory Distress SyndromeNoninvasive VentilationOxygen Inhalation TherapyARFHFNCOxygenGeneral-wardsDyspneaAHRFICU-supervisionPatients' RoomsCannulaHumansSafetyRespiratory InsufficiencyAgedRetrospective Studies
researchProduct